Théophile Ohlmann, Tassin la Demi-Lune (FR); Philippe Mangeot, Lyons (FR); and Emiliano Ricci, Lyons (FR)
Assigned to Institut National De La Sante Et De La Recherche Medicale (INSERM), Paris (FR); Centre National De La Recherche Scientifique (CNRS), Paris (FR); Ecole Normale Superieure De Lyon, Lyons (FR); and Universite Claude Bernard Lyon 1, Villeurbanne (FR)
Filed by Institut National De La Sante Et De La Recherche Medicale (INSERM), Paris (FR); Centre National De La Recherche Scientifique (CNRS), Paris (FR); Ecole Normale Superieure De Lyon, Lyons (FR); and Universite Claude Bernard Lyon 1, Villeurbanne (FR)
Filed on Apr. 3, 2023, as Appl. No. 18/130,375.
Application 18/130,375 is a continuation of application No. 17/174,405, filed on Feb. 12, 2021, granted, now 11,649,264.
Application 17/174,405 is a continuation of application No. 15/769,534, granted, now 10,968,253, issued on Apr. 6, 2021, previously published as PCT/EP2016/075289, filed on Oct. 20, 2016.
Claims priority of application No. 15306678 (EP), filed on Oct. 20, 2015.
Prior Publication US 2024/0132547 A1, Apr. 25, 2024 Prior Publication US 2024/0228546 A9, Jul. 11, 2024
1. A retrovirus-derived particle comprising one or more Cas protein(s), wherein the one or more Cas protein(s) is inside of said particle as a fusion protein between (i) a retroviral gag protein and (ii) the one or more Cas protein(s), wherein the one or more Cas protein(s) is complexed with one or more CRISPR-Cas guide RNA(s).